Corporate Banner
Satellite Banner
ADME Tox
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

CyBio to be Merged into Analytik Jena

Published: Friday, April 11, 2014
Last Updated: Friday, April 11, 2014
Bookmark and Share
Analytik Jena AG is planning to merge the business of its subsidiary CyBio AG with its core business in the Life Science business unit.

Against this backdrop, CyBio AG will be merged into Analytik Jena AG during the current financial year. A corresponding merger by absorption agreement was signed this past Friday.

As part of the merger by absorption, Analytik Jena AG plans to acquire all the remaining shares of CyBio AG by means of a method to squeeze out minority shareholders (known as a squeeze-out merger). The shareholders of CyBio AG are to draft a resolution to transfer the shares of the minority shareholders to Analytik Jena AG as the majority shareholder in return for payment of compensation in cash at the Company's General Meeting on May 22, 2014. Analytik Jena AG currently holds 91.9% of the voting rights of CyBio AG. 

The business activities of the CyBio Group are to be continued after the merger becomes effective and to be expanded in the coming years. CyBio products and services will continue to be marketed as an independent CyBio product line under the CyBio brand by Analytik Jena AG. CyBio AG currently employs 98 staff members around the world and is fully consolidated in the Analytik Jena Group. Analytik Jena AG already acquired the majority of the shares of CyBio AG in 2009.

"With the strategic and operational realignment of CyBio AG, we have consistently driven business in a customer-oriented way in the areas of liquid handling and laboratory automation technology in the past five years as part of the Analytik Jena Group. CyBio AG has become an integral and successful part of the Analytik Jena AG family," said Klaus Berka, Chief Executive Officer of Analytik Jena AG. "The planned merger and structural integration is the logical continuation of this path with the aim of bundling our competencies in the Group portfolio and thus providing access for our customers to an even more comprehensive range." 


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
'Kidney on a Chip' Facilitates Safer Drug Dosing
University of Michigan researchers have used a "kidney on a chip" device to mimic the flow of medication through human kidneys and measure its effect on kidney cells.
Ketamine Metabolism Lifts Depression
NIH-funded team finds rapid-acting, non-addicting agent in mouse study.
Turning Skin Cells into Heart, Brain Cells
In a major breakthrough, scientists at the Gladstone Institutes transformed skin cells into heart cells and brain cells using a combination of chemicals.
Growing Stem Cells More Safely
Nurturing stem cells atop a bed of mouse cells works well, but is a non-starter for transplants to patients – Brown University scientists are developing a synthetic bed instead.
Cell Transplant Treats Parkinson’s in Mice
A University of Wisconsin—Madison neuroscientist has inserted a genetic switch into nerve cells so a patient can alter their activity by taking designer drugs that would not affect any other cell.
Understanding Female HIV Transmission
Glowing virus maps points of entry through entire female reproductive tract for first time.
Experimental Drug Cancels Effect from Key Intellectual Disability Gene
A University of Wisconsin—Madison researcher who studies the most common genetic intellectual disability has used an experimental drug to reverse — in mice — damage from the mutation that causes the syndrome.
Common Class of Cancer Drugs May Not Lead to Cognitive Decline
UCLA study refutes 2015 research suggesting anthracyclines could cause memory loss, other impairments.
Designing Better Drugs
A rational drug engineering approach could breathe new life into drug development.
Genetic Approach May Lead to New Treatments for Digestive Diseases
Researchers at UMass Medical School have identified a new molecular pathway critical for maintaining the smooth muscle tone that allows the passage of materials through the digestive system.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!